CHUKYO IYAKUHIN CO.,LTD.

4558 TSE Pharmaceuticals Pharmaceutical
TSE Standard
¥201.00
+0.50%
Delayed · cached 15 min

Fair value analysis

4558
CHUKYO IYAKUHIN CO.,LTD.
PharmaceuticalsPharmaceutical
¥201.00
Close used for this calculation
¥153.76Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
43/100
Profitability17/25
Returns4/25
Balance Sheet13/25
Efficiency9/25
Growth15/25
Average
Quality radar
43Prof.17/25Ret.4/25Eff.9/25B.Sht13/25Growth15/25

Consensus fair value

¥153.76
Above FV
▼ -23.5% against the close used
Model range ¥79.43 – ¥270.26
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥79.43Fair value¥153.76Bull¥270.26
FairClose
52-week traded range
52W low ¥197.0052W high ¥218.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

CHUKYO IYAKUHIN CO.,LTD. closed at ¥201.00, 30.7% above the consensus fair value of ¥153.76 drawn from 9 valuation models.

Financial DNA score 43/100 — Average. P/E of 25.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
¥108.60
-46.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
¥206.68
+2.8%
√(22.5 × EPS × BVPS)
EPS=7.84, BVPS=242.17
P/E Fair Value
¥156.80
-22.0%
EPS × 20x (sector P/E)
EPS=7.84, Sector P/E=20x
Peter Lynch (PEG)
¥203.53
+1.3%
EPS × Growth% (PEG = 1 is fair)
EPS=7.84, g=26%
EV/EBITDA
¥178.12
-11.4%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=173.94M
Dividend Discount (DDM)
¥270.26
+34.5%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=5, r=10%, g=8%
Book Value (P/B)
¥79.43
-60.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=242.17, ROE=3.3%, g=6%, r=10%
Reverse DCF
¥201.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 10.5% | Historical: 26%
Margin of Safety
¥118.02
-41.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=157.36, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.